Under the agreement, ImmunoPrecise will use Zymeworks' Azymetric and Efect platforms to further develop multiple COVID-19 monospecific antibody candidates by transforming them into bispecific and multispecific antibodies, the companies said.

Immunoprecise highlights combo neutralization of antibodies
Immunoprecise Antibodies has conducted additional characterization of a subset of fully human, therapeutic SARS-CoV-2 antibodies that are potent and exhibit...

Zymeworks, Merck to develop multispecific antibodies
Merck has signed a research and licensing agreement to develop multispecific antibody therapeutic candidates using platforms from clinical-stage biopharmaceutical...

ImmunoPrecise identifies SARS-CoV-2 neutralizing antibodies
ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further...

ImmunoPrecise, NIH, Integrated Biotherapeutics test antibodies for COVID-19
ImmunoPrecise Antibodies announced that it is collaborating with the National Institute of Diabetes and Digestive and Kidney Diseases at the National...

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...